High-dose adriamycin (ADM) and cis-platinum (DDP) in advanced soft-tissue sarcomas and invasive thymomas. A pilot study

Cancer Chemother Pharmacol. 1984;13(2):78-81. doi: 10.1007/BF00257118.

Abstract

Eighteen previously untreated patients with advanced unresectable or metastatic soft-tissue sarcomas (STS) and two patients with locally invasive thymoma were treated with a combination of adriamycin (ADM) 80 mg/m2 on day 1 and cis-platinum (DDP) 120 mg/m2 on day 1. The regimen was repeated at 4-weeks intervals. In STS the overall remission rate was 44%, with 21% complete remissions. The overall survival was 15 months (3-35+), responders surviving a median of 20 months (3-35+) and nonresponders, a median of 9 months (3-20+). Tumor responses lasted a median of 8 months (3-35+). Two patients with liposarcoma have now survived disease-free for at least 2 years and are potentially cured. The two patients with thymoma experienced complete remission lasting 4+ and 20+ months. Substantial hematologic toxicity was prominent, due to the high-doses used in this combination regimen.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Sarcoma / drug therapy*
  • Sarcoma / mortality
  • Soft Tissue Neoplasms / drug therapy*
  • Soft Tissue Neoplasms / mortality
  • Thymoma / drug therapy*
  • Thymoma / mortality
  • Thymus Neoplasms / drug therapy*
  • Thymus Neoplasms / mortality
  • Time Factors

Substances

  • Doxorubicin
  • Cisplatin